アジア太平洋のセルベースアッセイ市場： 分析と予測（2023年～2032年）

アジア太平洋のセルベースアッセイの市場規模は2032年までに91億9,000万米ドルに達すると予測されています。

アジア太平洋のセルベースアッセイ市場は、2023年に40億5,000万米ドルと評価され、2032年には91億9,000万米ドルに達すると予測されており、予測期間の2023年～2032年のCAGRは9.53%になるとみられています。セルベースアッセイ市場は、製薬業界における創薬活動の増加や、従来の方法と比較してこれらのアッセイが提供する優れた利点に後押しされ、急速な成長を遂げています。ヒトの生理機能を再現し、薬剤の有効性と安全性を予測し、治療法を調整する機能が市場の需要を牽引しています。この成長は、慢性疾患の罹患率の増加や政府の支援策によっても後押しされ、市場は大幅に拡大する見込みです。

アジア太平洋のセルベースアッセイ市場は、同地域における医薬品の研究開発活動の活発化により、大幅な成長を遂げています。セルベースアッセイは、従来の方法に比べて大きな利点があり、様々な産業での採用を促進しています。アジア太平洋の人口基盤の大きさ、慢性疾患の罹患率の増加、政府の支援政策が市場拡大をさらに後押ししています。さらに、ヘルスケアインフラの進歩やバイオテクノロジー・製薬部門への投資の増加が市場の勢いに寄与しています。個別化医療と早期薬効予測に重点を置くアジア太平洋地域は、世界のセルベースアッセイ市場の主要地域として台頭しており、継続的な成長と革新の態勢を整えています。

当レポートでは、アジア太平洋のセルベースアッセイ市場について調査し、市場の概要とともに、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 調査範囲

第2章 調査手法

第3章 市場の概要

• 市場イントロダクション
  • セルベースアッセイの種類
  • セルベースアッセイ会社への影響

第4章 業界考察

• 概要
• 米国の法的要件と枠組み
• 欧州の法的要件と枠組み
• アジア太平洋における法的要件と枠組み
  • 日本の法的要件と枠組み

第5章 市場力学

• 概要
• 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第6章 セルベースアッセイ市場（地域別）、10億米ドル、2022年～2032年

• 概要
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • その他の地域

List of Figures

• Figure 1: Impact Analysis of Drivers, Challenges, and Opportunities on the Cell-Based Assay Market
• Figure 2: Cell-Based Assay Market (by Region), 2022
• Figure 3: Cell-based Assay Market Methodology
• Figure 4: Primary Research Methodology
• Figure 5: Top-Down Approach (Segment-Wise Analysis)
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Cellular Processes Utilized to Investigate the Impacts in Cell-Based Assays
• Figure 8: Emerging Technologies in the Cell-Based Assay Market
• Figure 9: Asia-Pacific Cell-Based Assay Market, $Billion, 2022-2032
• Figure 10: Impact of COVID-19 on Cell-Based Assay Companies
• Figure 11: Cell-Based Assay Market - Market Dynamics
• Figure 12: Total U.S. Life Sciences Venture Capital Funding, $Billion, 2016-2021
• Figure 13: Uses of Cell-based Assays in Regenerative Medicine
• Figure 14: Cell-Based Assay Market Snapshot (by Region)
• Figure 15: Cell-Based Assay Market (by Region), $Billion, 2022-2032
• Figure 16: Asia-Pacific Cell-Based Assay Market, $Billion, 2022-2032
• Figure 17: Asia-Pacific: Market Dynamics
• Figure 18: Asia-Pacific Cell-Based Assay Market (by Country), $Billion, 2022-2032
• Figure 19: China Cell-Based Assay Market, $Billion, 2022-2032
• Figure 20: Japan Cell-Based Assay Market, $Billion, 2022-2032
• Figure 21: India Cell-Based Assay Market, $Billion, 2022-2032
• Figure 22: South Korea Cell-Based Assay Market, $Billion, 2022-2032
• Figure 23: Australia Cell-Based Assay Market, $Billion, 2022-2032
• Figure 24: Rest-of-Asia-Pacific Cell-Based Assay Market, $Billion, 2022-2032
• Figure 25: Total Number of Companies Profiled

List of Tables

• Table 1: Current and Future State of Cell-Based Assay in Industries
• Table 2: Utilizing the Potential of Cell-Based Assays: Novel Instruments and Methodologies in 2020-2021

The Asia-Pacific Cell-Based Assay Market Expected to Reach $9.19 Billion by 2032

Introduction to Asia-Pacific Cell-Based Assay Market

The Asia-Pacific cell-based assay market was valued at $4.05 billion in 2023 and is anticipated to reach $9.19 billion by 2032, witnessing a CAGR of 9.53% during the forecast period 2023-2032. The Cell-Based Assay Market is experiencing rapid growth, propelled by increased drug discovery activities in the pharmaceutical industry and the superior benefits these assays offer compared to conventional methods. Their capability to replicate human physiology, forecast drug effectiveness and safety, and tailor treatments drives market demand. This growth is also fueled by the growing incidence of chronic diseases and government support initiatives, creating a market set for substantial expansion.

Market Introduction

The Asia-Pacific (APAC) Cell-Based Assay Market is witnessing substantial growth due to heightened pharmaceutical research and development activities in the region. Cell-based assays offer significant advantages over traditional methods, driving their adoption across various industries. APAC's large population base, increasing incidence of chronic diseases, and supportive government policies are further propelling market expansion. Additionally, advancements in healthcare infrastructure and rising investments in biotechnology and pharmaceutical sectors contribute to the market's momentum. With a focus on personalized medicine and early drug efficacy prediction, the APAC region is emerging as a key player in the global cell-based assay market, poised for continued growth and innovation.

Market Segmentation

Segmentation 1: by Country

• China
• Japan
• India
• South Korea
• Australia
• Rest-of-Asia-Pacific

How can this report add value to an organization?

Growth/Marketing Strategy: The APAC cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.

Competitive Strategy: Key players in the APAC cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1 Research Scope

• 1.1 Key Questions Answered in the Report:

2 Research Methodology

• 2.1 Cell-Based Assay Market: Research Methodology
• 2.2 Primary Data Sources
• 2.3 Secondary Data Sources
• 2.4 Market Estimation Model
• 2.5 Criteria for Company Profiling

3 Markets Overview

• 3.1 Market Introduction
  • 3.1.1 Types of Cell-Based Assays
• 3.2 Current and Future State of Cell-Based Assays in Industries
• 3.3 Emerging Technologies and Applications in the Cell-Based Assay Market
• 3.4 Current Market Size and Growth Potential, $Billion, 2022-2032
• 3.5 COVID-19 Impact on Cell-Based Assay Market
  • 3.5.1 Impact on Cell-Based Assay Companies

4 Industry Insights

• 4.1 Overview
• 4.2 Legal Requirements and Frameworks in the U.S.
• 4.3 Legal Requirements and Frameworks in Europe
• 4.4 Legal Requirements and Frameworks in Asia-Pacific
  • 4.4.1 Legal Requirements and Frameworks in Japan

5 Market Dynamics

• 5.1 Overview
• 5.2 Impact Analysis
  • 5.2.1 Market Drivers
    • 5.2.1.1 Increase in Demand for Cell-Based Assay in Drug Discovery and Development
    • 5.2.1.2 Rise in Life Sciences Research Investments
    • 5.2.1.3 Technological Advancements
  • 5.2.2 Market Restraints
    • 5.2.2.1 High Cost
    • 5.2.2.2 Lack of Standardization
  • 5.2.3 Market Opportunities
    • 5.2.3.1 Increased Focus on Regenerative Medicine
    • 5.2.3.2 Emergence of Novel Gene Editing Technologies

6 Cell-Based Assay Market (by Region), $Billion, 2022-2032

• 6.1 Overview
• 6.2 Asia-Pacific
  • 6.2.1 China
  • 6.2.2 Japan
  • 6.2.3 India
  • 6.2.4 South Korea
  • 6.2.5 Australia
  • 6.2.6 Rest-of-Asia-Pacific